At the time of writing, Valve has still not confirmed the official price of the Steam Machine, but it may have accidentally ...

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in ...

This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline ...

GSK on Tuesday said Japan’s Ministry of Health, Labour and Welfare approved Exdensur, also known as depemokimab, for patients ...

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...